OncoSil Medical Ltd (ASX: OSL) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Oncosil Medical Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $35.26 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 792.34 million
Earnings per share -0.013
Dividend per share N/A
Year To Date Return -2.22%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

OncoSil Medical Ltd (ASX: OSL)
Latest News

OSL ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About OncoSil Medical Ltd

OncoSil Medical Ltd is a medical device company focused on localized radiation treatments for patients with pancreatic and bile duct cancer. Its product includes OncoSil, a silicon and phosphorus (p32) beta emitter radiation therapy for the treatment of pancreatic cancer.

OSL Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
17 Jan 2022 $0.04 $0.00 0.00% 624,266 $0.04 $0.04 $0.04
14 Jan 2022 $0.04 $0.00 0.00% 292,110 $0.04 $0.04 $0.04
13 Jan 2022 $0.04 $0.00 0.00% 479,088 $0.04 $0.04 $0.04
12 Jan 2022 $0.05 $0.00 0.00% 51,609 $0.04 $0.05 $0.04
11 Jan 2022 $0.04 $0.00 0.00% 57,817 $0.05 $0.05 $0.04
10 Jan 2022 $0.05 $0.00 0.00% 225,035 $0.04 $0.05 $0.04
07 Jan 2022 $0.05 $0.00 0.00% 295,351 $0.05 $0.05 $0.04
06 Jan 2022 $0.05 $0.00 0.00% 600,766 $0.05 $0.05 $0.04
05 Jan 2022 $0.05 $0.00 0.00% 3,100,653 $0.05 $0.05 $0.05
04 Jan 2022 $0.05 $0.00 0.00% 597,176 $0.05 $0.05 $0.05
31 Dec 2021 $0.05 $0.00 0.00% 420,746 $0.05 $0.05 $0.05
30 Dec 2021 $0.04 $0.00 0.00% 1,254,886 $0.05 $0.05 $0.04
29 Dec 2021 $0.05 $0.01 23.26% 2,197,888 $0.05 $0.05 $0.04
24 Dec 2021 $0.04 $0.00 0.00% 5,404,840 $0.04 $0.05 $0.04
23 Dec 2021 $0.04 $0.00 0.00% 452,461 $0.04 $0.04 $0.04
22 Dec 2021 $0.04 $0.00 0.00% 756,864 $0.04 $0.04 $0.04
21 Dec 2021 $0.04 $0.00 0.00% 803,029 $0.04 $0.04 $0.04
20 Dec 2021 $0.04 $0.00 0.00% 198,286 $0.04 $0.04 $0.04

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
20 Oct 2021 Nigel Lange Issued 2 $153,448
Issue of securities. 2,841,633 - Performance Rights
24 Aug 2021 Martin Cross Buy 95 $4,845
On-market trade.
10 May 2021 Christopher Roberts Cancelled 10 $900,000
Cancellation of securities. As per announcement on 10/05/2021.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Otto Leslie Steven Buttula Non-Executive Director Jul 2021
Mr Buttula has more than 30 years of experience in investment research, funds management and information technology. Formerly the co-founder, CEO and Managing director at IWL Limited, an online financial services company. Mr Buttula's executive experience includes former roles as the Managing Director of Investors Mutual and Lonsdale Securities, both companies he founded. He has also served on the Board of several public companies including roles as Non-Executive Chairman of platform and stockbroking provider Investorfirst, now HUB24 (ASX: HUB), and Non-Executive Director at Imugene Limited (ASX: IMU). Mr Buttula currently serves as Chairman at Rhythm Biosciences Limited (ASX: RHY) and HITIQ Limited (ASX: HIQ).
Mr Nigel Lange Chief Executive OfficerManaging Director Jan 2021
Mr Lange brings with him over 30 years of experience in the medical devices industry. Since 2003, Nigel has held various leadership roles with Sirtex Medical, a global leader in brachytherapy treatment for liver cancer. From 2003, Nigel served as Chief Executive Officer of Sirtex's European business, responsible for establishing their brachytherapy device in over 300 centres across Europe and Middle East. Since 2017, he served as Group Chief Commercial Officer where he was responsible for all commercial aspects of the global business. During this time, he has also held interim roles including Interim Group CEO and Interim CEO of Asia Pacific. Mr Lange is a member of Risk Committee.
Dr Martin George Cross Non-Executive Director Feb 2017
Dr Cross is a pharmaceutical executive with over 35 years' experience including corporate and industry leadership roles directly influencing healthcare policy and government legislation in Australia and global business management, marketing and sales roles. From 2013 to 2015, Dr Cross was Chairman of Medicines Australia, the country's peak body representing the research based pharmaceutical industry in Australia. Prior to leading Medicines Australia, from 2010 to 2013 Dr Cross was Chairman of both the Generics Medicine Industry Association and Pharmaceutical Industry Council. During this time, Dr Cross was also Managing Director of Alphapharm in Australia and New Zealand, with responsibility for 750 employees and sales of over US $500m per annum. From 2003 to 2008, Dr Cross was Country Head and Managing Director of Novartis Australia and New Zealand, and Head of Global Marketing and Sales Capabilities from 2001 to 2003, based in Switzerland. Dr Cross is a Non Executive Director of Cellmid Limited. Dr Cross is a member of Risk Committee.
Professor Ricky Sharma Non-Executive Director Nov 2021
Professor Sharma is an international authority on the translation of radiobiology from the laboratory to the clinic and on the multi-modality treatment of cancer with precision radiotherapy. He is currently Vice President Clinical Affairs at Varian, a Siemens Healthineers company. He is also an honorary consultant in clinical oncology at University College London Hospitals, where he has a clinical practice in radiotherapy and chemotherapy. He has led a research team at University College London that translated discoveries in radiotherapy research to clinical trials to improve treatment for patients with cancer. He was previously an associate professor at the University of Oxford, and an honorary consultant in clinical oncology at Oxford University Hospitals. He has over 200 publications in peerreviewed scientific journals, including Lancet and Nature journals. Professor Sharma has previously been the chair of radiation oncology at University College London and a scientific group leader at the UCL Cancer Institute and he was a former chair of working groups for NHS/NICE evaluations of novel radiotherapy treatments.
Mr Karl David Pechmann Chief Financial OfficerCompany Secretary Mar 2020
-
Karl David Pechmann Chief Financial OfficerCompany Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
National Nominees Limited 36,386,861 4.59%
Webinvest Pty Ltd (Olsb Unit A/C) 28,000,001 3.53%
Brispot Nominees Pty Ltd (House Head Nominee A/C) 27,034,820 3.41%
Netwealth Investments Limited (Wrap Services A/C) 24,105,032 3.04%
Rojo Nero Capital Pty Ltd 18,685,443 2.36%
Mr Gregory Joseph Harris 15,668,733 1.98%
Citicorp Nominees Pty Limited 14,343,188 1.81%
Mr Roger Aston 12,654,416 1.60%
Tisia Nominees Pty Ltd (Henderson Family A/C) 9,384,768 1.18%
HSBC Custody Nominees (Australia) Limited 7,993,877 1.01%
Mr Michael Warrener 6,962,673 0.88%
BNP Paribas Nominees Pty Ltd (Ib Au Noms Retailclient Drp) 6,905,749 0.87%
Ematt Securities Pty Ltd (National Equities Sfund A/C) 6,252,000 0.79%
Ms Nicole Wilson 6,099,005 0.77%
Alua Capital Pty Ltd 6,000,000 0.76%
Mr Nigel Lange 5,718,303 0.72%
BNP Paribas Nominees Pty Ltd Six Sis Ltd (DRP A/C) 5,439,928 0.69%
Asia Union Investments Pty Ltd 5,000,000 0.63%
Cabbit Pty Ltd (Robwill A/C) 4,636,364 0.59%
Neweconomy Com Au Nominees Pty Limited (900 Account) 4,479,660 0.57%

Profile

since

Note